NCI’s Frederick National Laboratory for Cancer Research has launched three initiatives focused on SARS-CoV-2.
In spite of disruptions caused by the coronavirus pandemic, NCI continues to review grants, disburse funds, and support extramural research, said NCI Director Ned Sharpless.
The phase III confirmatory ASCENT study—designed to validate the promising safety and efficacy data of sacituzumab govitecan observed in a phase II study of heavily pretreated patients with metastatic triple negative breast cancer—will be halted due to compelling evidence of efficacy.
Following physical activity guidelines from the U.S. Department of Health and Human Services can improve clinical outcomes for patients with high-risk breast cancer, according to a study published in the Journal of the National Cancer Institute.
A drug combination discovered by the UT Southwestern Simmons Cancer Center may extend the effectiveness of a lung cancer treatment and make it available to many more patients.
FDA has approved Braftovi (encorafenib) in combination with Erbitux (cetuximab) for the treatment of adult patients with metastatic colorectal cancer with a BRAFV600E mutation, as detected by an FDA-approved test, after prior therapy.
FDA has approved luspatercept-aamt (Reblozyl, sponsored by Celgene Corp) for the treatment of anemia failing an erythropoiesis stimulating agent and requiring 2 or more red blood cell units over 8 weeks in adult patients with very low- to intermediate-risk myelodysplastic syndromes with ring sideroblasts or with myelodysplastic/myeloproliferative neoplasm with ring sideroblasts and thrombocytosis.
Myriad Genetics has received reimbursement and launched the BRACAnalysis Diagnostic System in Japan to help physicians determine which people affected with breast and ovarian cancer have hereditary breast and ovarian cancer syndrome and qualify for additional diagnostic and medical management.
The FY20 Defense Appropriations Act is anticipated to provide funding to the Department of Defense Ovarian Cancer Research Program to support patient-centered research to prevent, detect, treat, and cure ovarian cancer.
The American Society of Clinical Oncology April 9 published a set of recommendations to support the oncology community as health care institutions across the United States face potentially difficult decisions around the allocation of scarce health care resources during the COVID-19 pandemic.
